Existing heart drugs may help cancer patients respond better to PD(L)1 immunotherapy
Scienmag
OCTOBER 21, 2020
Researchers have found that a class of commonly-used heart drugs may also improve patients’ responses to anti-cancer immunotherapies called PD(L)1 inhibitors, according to preliminary findings to be presented at the 32th EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics, which is taking place online.
73 
Let's personalize your content